Serentil®

A boxed WARNING has been added to prominently advise clinicians that Serentil® has been shown to prolong the QTc interval in a dose related manner, and drugs with this potential, including Serentil®, have been associated with torsade de pointes-type arrhythmias and sudden death.

Serentil® is now indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects. Serentil® has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.

Serentil® is contraindicated with other drugs known to prolong the QTc interval.

Source: fda.gov

If you or a loved one has been harmed by Serentil®, you may want to contact a Serentil® attorney for more information.